retatrutide phase 2 nejm weight loss 48 weeks Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide dose: the complete guide

What kind of weight you lose matters enormously

Overview of Depression Major depressive disorder (MDD) is a highly prevalent mood disorder characterized by ruminative thoughts, impaired cognition and anhedonia, and attentional control deficits (Marchetti et al., 2012

Hot Ultrasound Waves Visibly Tightened My Loose Arm Skin Sofwave, a non-invasive high-frequency device, toned my arms when weight lifting couldn't

Its meant to be taken once daily, and is currently FDA-approved for adults with type 2 diabetes

Your doctor might need to look at adjusting your other medicines, but it is vitally important to only make changes to your medication on the advice of your doctor

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide carry the clinical evidence: STEP for semaglutide ( The New England Journal of Medicine , 2021), SURMOUNT for tirzepatide (NEJM, 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM, 2024)